Randomized controlled study of chemoimmunotherapy with <font color="blue">bestatin_1</font> <font color="blue">of_1</font> <font color="blue">acute_5</font> <font color="blue">nonlymphocytic_5</font> <font color="blue">leukemia_5</font> <font color="blue">in_5</font> <font color="blue">adults_5</font> <font color="blue">._5</font> <font color="blue">
<br>
<br>_2</font> A new immunomodulating agent , bestatin ( INN : Ubenimex has low toxicity even after long - term oral administration and has significant modifications in immunological response . A cooperative randomized controlled study of bestatin immunotherapy in combination with remission maintenance chemotherapy for <font color="blue">adult_4</font> <font color="blue">acute_4</font> <font color="blue">nonlymphocytic_4</font> <font color="blue">leukemia_4</font> <font color="blue">(_4</font> <font color="blue">ANLL_4</font> <font color="blue">)_4</font> was performed . After induction of complete remission , <font color="blue">patients_1</font> were randomized to the bestatin group ( 30 mg / bw per os ( po ) daily ) and the control group . <font color="blue">The_1</font> <font color="blue">101_4</font> <font color="blue">eligible_4</font> <font color="blue">cases_4</font> <font color="blue">(_3</font> <font color="blue">bestatin_3</font> <font color="blue">:_3</font> <font color="blue">48_3</font> <font color="blue">,_3</font> <font color="blue">control_3</font> <font color="blue">:_3</font> <font color="blue">53_3</font> <font color="blue">)_3</font> were analyzed ; the bestatin group achieved longer remission than the control group and a statistically significant longer survival . Though this prolongation of remission was not significant in the bestatin group compared to the control group in the <font color="blue">15_1</font> <font color="blue">-_1</font> <font color="blue">49_1</font> <font color="blue">yr_1</font> <font color="blue">age_1</font> <font color="blue">group_1</font> <font color="blue">,_1</font> in the <font color="blue">50_1</font> <font color="blue">-_1</font> <font color="blue">65_1</font> <font color="blue">yr_1</font> <font color="blue">age_1</font> <font color="blue">group_1</font> it was significantly longer . Bestatin is shown to be a clinically useful drug for immunotherapy of <font color="blue">adult_1</font> <font color="blue">ANLL_1</font> <font color="blue">,_1</font> since it has prolonged survival and remission especially in elderly patients , with few side - effects .